Pluristem Therapeutics: annual report for the year ended Jun 30, 2019
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0001213900-19-017859
- Document
- 10-K
- Exhibit 4.3
- Description of securities
- Exhibit 10.8
- Summary of directors ongoing compensation
- Exhibit 10.18
- Stock option agreement
- Exhibit 10.19
- Restricted stock agreement
- Exhibit 10.20
- Restricted stock agreement for israelis
Not explained yet; the original is on EDGAR.
Similar companies
Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.
- ProPhase Labs PRPH public float $15M, Jun 30, 2025
- Akari Therapeutics AKTX public float $15M, Jun 30, 2025
- X4 Pharmaceuticals XFOR public float $15M, Jun 30, 2025
- CalciMedica CALC public float $16M, Jun 30, 2025
- Lipocine LPCN public float $16M, Jun 30, 2025
